- Olympus cuts its full-year operating income forecast to 176 billion yen.
- Previous forecast for operating income was 177 billion yen; the estimate was 172.6 billion yen.
- Net sales forecast adjusted to 1.01 trillion yen, down from 1.02 trillion yen; the estimate was 1.02 trillion yen.
- Net income forecast remains at 121 billion yen, close to the estimate of 120.27 billion yen.
- Dividend remains at 20 yen per share, slightly below the estimate of 20.49 yen.
- First quarter operating income was 27.48 billion yen, a 22% year-on-year increase, but below the estimate of 29.36 billion yen.
- First quarter net income fell sharply by 94% year-on-year to 14.58 billion yen, below the estimate of 19.59 billion yen.
- First quarter net sales were 234.82 billion yen, a 13% increase year-on-year, beating the estimate of 232.57 billion yen.
- Endoscopic Solutions revenue for the first quarter was 147.39 billion yen, a 16% increase year-on-year, but slightly below the estimate of 147.92 billion yen.
- Therapeutic Solutions revenue for the first quarter was 87.28 billion yen, a 13% increase year-on-year, but slightly lower than the estimate of 87.87 billion yen.
- Analyst recommendations include 12 buys, 3 holds, and 0 sells.
Olympus Corp on Smartkarma
Independent analysts on Smartkarma, such as Tina Banerjee, have been closely monitoring Olympus Corp (7733 JP) and providing valuable insights for investors. In one analysis titled “Olympus Corp (7733 JP): Β₯100B Buyback Plan Offers an Attractive Exit Opportunity Amid Bleak Outlook,” it was highlighted that the company has announced a Β₯100B buyback plan until December 2024. Despite a bleak business outlook and limited upside potential, the recommendation was to consider tendering shares given the buyback offer representing 5.15% of outstanding shares.
Another report by the same analyst, titled “Olympus Corp (7733 JP): Q3 Operating Profit Misses Estimates Despite Sales Beat; FY24 Guidance Cut,” detailed disappointing Q3 results for Olympus Corp, with revenue surpassing estimates but operating profit declining significantly. The company had to reduce its FY24 sales guidance mainly due to the impact of a recent earthquake. Looking ahead to FY25, although improvements in revenue and profits are expected, challenges remain in achieving a targeted operating margin of 20% and sales growth of 5% as outlined in the analysis.
A look at Olympus Corp Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 2 | |
Dividend | 2 | |
Growth | 5 | |
Resilience | 3 | |
Momentum | 5 | |
OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Olympus Corp shows a promising long-term outlook. With a high score in Growth and Momentum, the company seems well-positioned for future success. The strong momentum indicates positive market sentiment towards Olympus, while the high growth score suggests potential for expansion and profitability in the future. Additionally, the company demonstrates decent Resilience, indicating a certain level of stability. Although Value and Dividend scores are moderate, the overall outlook for Olympus Corp appears positive as it continues to innovate and grow in the optoelectronic products market.
Olympus Corporation, a manufacturer of optoelectronic products, has received a mix of scores in different areas. Specializing in cameras, endoscopes, microscopes, and more, the company has excelled in Growth and Momentum, indicating a bright future ahead. While Value and Dividend scores are average, Olympus Corp‘s strong performance in Growth and Momentum suggests potential for continued success and market appeal. Moreover, the company’s range of products, including medical and industrial devices, paint a picture of innovation and diversification in the optoelectronic industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars